Novo Nordisk A/S (NVO) Shares Bought by First Trust Advisors LP

First Trust Advisors LP lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 4,736.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 466,631 shares of the company’s stock after purchasing an additional 456,983 shares during the period. First Trust Advisors LP’s holdings in Novo Nordisk A/S were worth $21,521,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Loomis Sayles & Co. L P grew its holdings in shares of Novo Nordisk A/S by 6.4% during the first quarter. Loomis Sayles & Co. L P now owns 22,025,113 shares of the company’s stock worth $1,084,737,000 after purchasing an additional 1,323,857 shares during the last quarter. Fisher Asset Management LLC grew its holdings in shares of Novo Nordisk A/S by 3.4% during the second quarter. Fisher Asset Management LLC now owns 13,569,671 shares of the company’s stock worth $625,833,000 after purchasing an additional 440,014 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Novo Nordisk A/S by 2.9% during the first quarter. BlackRock Inc. now owns 9,695,784 shares of the company’s stock worth $477,518,000 after purchasing an additional 272,500 shares during the last quarter. Sustainable Growth Advisers LP grew its holdings in shares of Novo Nordisk A/S by 3.3% during the first quarter. Sustainable Growth Advisers LP now owns 3,937,893 shares of the company’s stock worth $193,942,000 after purchasing an additional 125,614 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of Novo Nordisk A/S by 1.4% during the first quarter. Northern Trust Corp now owns 2,047,519 shares of the company’s stock worth $100,841,000 after purchasing an additional 27,532 shares during the last quarter. Institutional investors own 6.75% of the company’s stock.

Several analysts have recently commented on the company. Zacks Investment Research upgraded Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Tuesday, July 31st. Sanford C. Bernstein upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Monday, July 2nd. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $64.00.

Novo Nordisk A/S stock opened at $47.77 on Friday. The stock has a market capitalization of $114.53 billion, a P/E ratio of 20.36, a PEG ratio of 2.52 and a beta of 0.66. Novo Nordisk A/S has a 12-month low of $44.28 and a 12-month high of $58.37.

The company also recently declared a special dividend, which will be paid on Tuesday, August 28th. Investors of record on Monday, August 20th will be issued a $0.4669 dividend. This represents a yield of 1.72%. The ex-dividend date of this dividend is Friday, August 17th. Novo Nordisk A/S’s dividend payout ratio is 38.89%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.

Read More: Average Daily Trade Volume Explained

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply